1. DOP36 Gut microbial variations in patients with quiescent Crohn's disease predict subsequent disease flare. (25th January 2019) Authors: Braun, T; Di Segni, A; BenShoshan, M; Neuman, S; Picard, O; Sosnovski, K; Efroni, G; Weiss, B; Yablecovitch, D; Lahat, A; Eliakim, R; Kopylov, U; Ben-Horin, S; Haberman, Y Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S046 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. DOP62 A novel formulation of CT-P13 (infliximab biosimilar) for subcutaneous administration: 1-year result from a Phase I open-label randomised controlled trial in patients with active Crohn's disease. (25th January 2019) Authors: Reinisch, W; Jang, B I; Borzan, V; Lahat, A; Pukitis, A; Osipenko, M; Mostovoy, Y; Schreiber, S; Ben-Horin, S; Lee, S J; Suh, J H; Lee, S G; Lee, J H; Ye, B D Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S066 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. DOP86 Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn's disease: A phase 3, randomised, placebo-controlled study (LIBERTY-CD). (30th January 2023) Authors: Colombel, J F; Hanauer, S B; Sandborn, W; Sands, B E; Schreiber, S; Danese, S; Kierkus, J; Kulynych, R; Klopocka, M; Lahat, A; Gonciarz, M; Osipenko, M; Borzan, V; Kowalski, M; Saenko, D; Sardinov, R; Kim, S; Bae, Y; Lee, S; Yang, S Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i161 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Oral administration of non-absorbable delayed release 6-mercaptopurine is locally active in the gut, exerts a systemic immune effect and alleviates Crohn's disease with low rate of side effects: results of double blind Phase II clinical trial. (14th July 2015) Authors: Israeli, E; Goldin, E; Fishman, S; Konikoff, F; Lavy, A; Chowers, Y; Melzer, E; Lahat, A; Mahamid, M; Shirin, H; Nussinson, E; Segol, O; Ben Ya'acov, A; Shabbat, Y; Ilan, Y Journal: Clinical and experimental immunology Issue: Volume 181:Number 2(2015:Aug.) Page Start: 362 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P004 Untargeted serum metabolome shows Crohn Disease (CD) associated signature, signals that correlate with disease activity and CRP, and signals that may precede disease flare. (30th January 2023) Authors: Levhar, N; Hadar, R; Braun, T; Efroni, G; Abramovich, I; Gottlieb, E; Granot, M; Sandra, N; Selinger, L; Picard, O; Yavzori, M; Lahat, A; Eliakim, R; Weiss, B; Kopylov, U; Ben-Horin, S; Amir, A; Haberman Ziv, Y Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i173 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P014 Untargeted serum metabolome in longitudinal Crohn's Disease (CD) cohort enrolled during remission shows strong individualized signature and CD-associated signals that are maintained also in patients who normalized their fecal calprotectin. (27th May 2021) Authors: Levhar, N; Hadar, R; Braun, T; Efroni, G; Abramovich, I; Gottlieb, E; Sosnovski, K; Abass, H; Berger, T; Granot, M; Neuman, S; Selinger, L; Picard, O; Yavzuri, M; Lahat, A; Eliakim, R; Weiss, B; Kopylov, U; Ben-Horin, S; Amir, A Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S135 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. P046 Crohn Disease (CD) untargeted fecal metabolome shows strong correlation with specific salivary associated microbial taxa, and with disease activity. (30th January 2023) Authors: Levhar, N; Hadar, R; Braun, T; Efroni, G; Abramovich, I; Gottlieb, E; Granot, M; Neuman, S; Selinger, L; Picard, O; Yavzori, M; Lahat, A; Eliakim, R; Weiss, B; Kopylov, U; Ben-Horin, S; Amir, A; Haberman Ziv, Y Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i213 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. P160 A novel PillCam Crohn's capsule score (Eliakim score) for quantification of mucosal inflammation in Crohn's disease. (15th January 2020) Authors: Eliakim, R; Yablecovitch, D; Lahat, A; Ungar, B; Shachar, E; Carter, D; Selinger, L; Neuman, S; Ben-Horin, S; Kopylov, U Journal: Journal of Crohn's and colitis Issue: Volume 14(2020)Supplement 1 Page Start: S218 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. P160 Pan-enteric mucosal inflammation in CD patients treated with vedolizumab – interim results of a prospective observational study using a panenteric capsule (PiilCam CD). (21st January 2022) Authors: Kopylov, U; Lipkin, M; Ungar, B; Haj, O; Shachar, E; Lahat, A; Ben-Horin, S; Eliakim, R Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i235 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. P173 Patency capsule: A novel independent predictor for long-term outcomes among patients with quiescent Crohn's disease. (30th January 2023) Authors: Ukashi, O; Kopylov, U; Ungar, B; Haj-Natour, O; Selinger, L; Neuman, S; Yanai, H; Dotan, I; Yablecovitch, D; Lahat, A; Eliakim, R; Ben-Horin, S Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i328 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗